Neural tube defects (NTDs) are congenital conditions characterized by incomplete closure of the neural tube during early development, resulting in structural openings in the brain or spinal cord. Examples of neural tube defects include encephalocele and spina bifida, and several recognized subtypes have been described within this broader category. Prevalence, age of onset, and population-specific patterns are not certified in this packet. Causative gene associations and molecular mechanisms are not certified in this packet.

Neural tube defects result from failure of the neural tube to close completely, producing openings in the brain or spinal cord. The specific clinical features associated with neural tube defects vary depending on the subtype and the location and extent of the structural abnormality. Detailed phenotype data, characteristic findings, and organ-system involvement are not certified in this packet. The recognized subtypes include conditions such as spina bifida, encephalocele, iniencephaly, diastematomyelia, lipomyelomeningocele, leptomyelolipoma, primary tethered cord syndrome, neurenteric cyst, isolated amyelia, parietal foramina, lateral meningocele syndrome, caudal regression sequence, and sacral agenesis-abnormal ossification of the vertebral bodies-persistent notochordal canal syndrome, each of which may present with distinct features.

Neural tube defects arise from incomplete closure of the neural tube during early fetal development. This packet does not certify a causative gene or set of genes for neural tube defects as a group. Inheritance pattern, molecular mechanism, and de novo rate data are not certified in this packet. The specific genetic or non-genetic contributors in any individual case are therefore not described here.

Specific diagnostic methods, testing hierarchies, biomarkers, and diagnostic criteria for neural tube defects are not certified in this packet. Newborn screening status is also not certified in this packet. Individual subtypes, such as spina bifida or encephalocele, may have distinct diagnostic considerations not detailed here.

Foundational therapies, FDA-approved treatments, and management protocols for neural tube defects as a group are not certified in this packet. Treatment coverage for this condition is unknown or not certified in this packet. Specific management approaches for individual subtypes are not described here.

Natural history and prognosis data for neural tube defects are not certified in this packet. The course and outlook are expected to vary considerably across the recognized subtypes, but no specific prognosis information can be described from the certified data available here.

Several certified active clinical trial records are present for neural tube defects. Among the certified trials, one study (NCT06734611) is examining folic acid salt supplementation (the Folic Acid Salt Study, FISFA Zambia), sponsored by the University of Alabama at Birmingham, with recruitment ongoing and an expected completion in 2028. Multiple studies are evaluating fetoscopic surgical approaches: a study of in-utero endoscopic correction of spina bifida (NCT04362592, University of Southern California) and a fetoscopic repair study for isolated fetal spina bifida (NCT03090633, Johns Hopkins University) are both active. A Phase 1 trial examining patch versus no-patch fetoscopic meningomyelocele repair (NCT03794011, Baylor College of Medicine) is also active. Additional recruiting studies address topics including bladder function and quality of life in spina bifida (NCT07642466), device safety and efficacy in fetoscopic neural tube defect repair (NCT05672849), and urinary impact of spinal dysraphism in the pediatric population (NCT07258654). Research publications associated with this condition include reviews, meta-analyses, case reports, and work in the areas of gene therapy and biomarkers. Active clinical trials for this condition are listed on ClinicalTrials.gov.